

ASX ANNOUNCEMENT

Appendix 4C – Quarterly Cash Flow Report

Highlights for the quarter ended 30th June 2018

- **Share options exercise and placement raises \$1,502k May 2018**
- **Cash balance as of 30th June, \$2,841k**
- **\$939k tax incentive paid April 2018**
- **Revolutionary PeriCoach[®] technique scoring demonstrates game changing success.**

31st July 2018: Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach[®] system and the AutoStart[®] and AutoFlush infusion system technologies, has today released its Appendix 4C - Quarterly Cashflow report for period ending 30th June 2018.

Receipts from sales of PeriCoach in Analytica's key markets of Australia, the UK and the US totalled \$1k, due to withdrawal of Pericoach from the US and refunds until manufacturing re-established. The marketing activity is focused on recruitment for data collection and feature development. Research & development expenditure was \$221k, dominated by expenditure on the PeriCoach "big data" project, the largest and most comprehensive pelvic floor muscle exercise database and analysis platform in the world. \$308k was incurred on staff costs. Administration costs of \$158k.

During the quarter, the company received \$1,531k of capital less 29k transaction cost.

The Board and management appreciate the confidence of our major shareholders for supporting the exercise of these options. These funds are being deployed to continue the development of the PeriCoach System and advance negotiations with potential partners.

Analytica received in April 2018, \$939k tax refund for research and development tax incentive for this last financial year. This is a much appreciated incentive by the Australian government to encourage the ground breaking research and development Analytica has been undertaking.

The company also has access to a \$400k loan facility. Directors are monitoring capital requirements to ensure the company has adequate cash to continue development and undertake partnering negotiations of the PeriCoach and the AutoFlush and AutoStart burette technologies. The Company continues to have the financial support of its major shareholders.

Research and development continue this quarter with further development of data analysis tools. Continued investment in real world data-gathering tools to increase the sophistication of analysis of user behaviour and pelvic health information is the cornerstone of company strategy.

Analytica is currently updating its quality system and bringing a new contract manufacturer online, with the aim of re-registering with the FDA and resume exporting product to the US this quarter.

Analytica is working closely with Navigant Capital Advisors LLC, (appointment, announced 6th November) with the process for the sale of the PeriCoach, AutoStart and AutoFlush.



As outlined in the Chairman's address to the Annual General Meeting in November 2017, Analytica is achieving its goals set out at the Annual General meeting 2016 of being deal-ready. This quarter demonstrates further strong progress to the Company strategy; build a product that is best in class, gather evidence that the product performance is exceptional, and actively pursue partnering opportunities.

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from pericoach.com in Australia and New Zealand, UK and Ireland.



Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Analytica Ltd

ABN

12 006 464 866

Quarter ended ("current quarter")

June 2018

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	1	46
1.2 Payments for		
(a) research and development	(221)	(1,215)
(b) product manufacturing and operating costs	(28)	(2)
(c) advertising and marketing	(27)	(124)
(d) leased assets		
(e) staff costs	(308)	(1,159)
(f) administration and corporate costs	(158)	(644)
1.3 Dividends received (see note 3)		
1.4 Interest received	5	12
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives	939	939
1.8 Other (provide details if material)	5	12
1.9 Net cash from / (used in) operating activities	208	(2,135)

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	(2)	(6)
(b) businesses (see item 10)		

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
(c) investments		
(d) intellectual property		
(e) other non-current assets		
2.2 Proceeds from disposal of:		
(a) property, plant and equipment		
(b) businesses (see item 10)		
(c) investments		
(d) intellectual property		
(e) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
2.5 Other (provide details if material)		
2.6 Net cash from / (used in) investing activities	(2)	(6)

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares	1,531	3,939
3.2 Proceeds from issue of convertible notes		
3.3 Proceeds from exercise of share options		
3.4 Transaction costs related to issues of shares, convertible notes or options	(29)	(169)
3.5 Proceeds from borrowings		
3.6 Repayment of borrowings		
3.7 Transaction costs related to loans and borrowings		
3.8 Dividends paid		
3.9 Other (provide details if material)		
3.10 Net cash from / (used in) financing activities	1,502	3,770

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	1,133	1,212
4.2 Net cash from / (used in) operating activities (item 1.9 above)	208	(2,135)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(2)	(6)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	1,502	3,770

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.5	Effect of movement in exchange rates on cash held		
4.6	Cash and cash equivalents at end of quarter	2,841	2,841

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	2,841	1,133
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	2,841	1,133

6. Payments to directors of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3

Current quarter \$A'000
96
0

- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

--

7. Payments to related entities of the entity and their associates

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3

Current quarter \$A'000

- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

--

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	400	0
8.2 Credit standby arrangements		
8.3 Other (please specify)		
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

--

9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	220
9.2 Product manufacturing and operating costs	40
9.3 Advertising and marketing	26
9.4 Leased assets	
9.5 Staff costs	320
9.6 Administration and corporate costs	170
9.7 Other (provide details if material)	
9.8 Total estimated cash outflows	776

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:
(Director)

Date:31st July 2018..

Print name: R. Mangelsdorf

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.